With Gilead (NASDAQ:GILD) paying $11 billion for Pharmasset last year, the action around the next generation of hepatitis C treatments has centered on nucleoside type products (“the nukes”). With Bristol-Myers (NYSE:BMY) halting clinical trials for its novel nuke, BMS-986094, for which investors had high expectations as it was part of the $2.5 billion acquisition of Inhibitex, analysts are calling for shares of GILD to trade up today. (more…)